Elicera Therapeutics (ELIC) Q2 2024 earnings summary

Executive summary

• Operating loss for Q2 2024 was SEK -5.8m, with a net loss of SEK -5.6m; H1 2024 operating loss was SEK -11.3m, net loss SEK -11.0m.

• Launched first clinical CAR T-cell study for lymphoma and signed collaboration agreements in China and the US.

• Board re-elected, new board member appointed, and rights issue of SEK 64m approved, with SEK 27.6m raised.

Financial highlights

• Q2 2024 operating loss increased to SEK -5.8m from SEK -4.5m year-over-year.

• Q2 net loss was SEK -5.6m, up from SEK -4.3m year-over-year.

• Cash flow from operating activities in Q2 was SEK -7.7m, compared to SEK -2.1m last year.

• H1 2024 EPS was SEK -0.39, compared to SEK -0.33 year-over-year.

Outlook and guidance

• First clinical CAR T-cell study (ELC-301) to enroll patients in autumn 2024, with interim data expected early 2025.

• Dose-escalation study results anticipated in H2 2025, with further results 6–12 months later, depending on recruitment.

• Final results from AdVince study expected in H2 2025.